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Abstract: Vectors based on adeno-associated virus (AAV) are promising tools for gene 
therapy. The production of strongly toxic vectors, for example for cancer-directed gene 
transfer,  is  often  unfeasible  due  to  uncontrolled  expression  of  toxic  genes  in  
vector-producing cells. Using an approach based on transcriptional repression, we have 
created novel AAV vectors carrying the genes coding for diphtheria toxin A (DTA) and the  
pro-apoptotic PUMA protein. The DTA vector had a significant toxic effect on a panel of 
tumor cell lines, and abrogation of protein synthesis could be shown. The PUMA vector 
had  a  toxic  effect  on  HeLa  and  RPMI  8226  cells,  and  sensitized  transduced  cells  to 
doxorubicin.  To  permit  targeted  gene  transfer,  we  incorporated  the  DTA  gene  into  a 
genetically  modified  AAV-2  capsid  previously  developed  by  our  group  that  mediates 
enhanced transduction of murine breast cancer cells in vitro. This vector had a stronger 
cytotoxic effect on breast cancer cells than DTA vectors with wildtype AAV capsid or 
vectors with a random capsid modification. The vector production and application system 
presented here allows for easy exchange of promotors, transgenes and capsid specificity for 
certain  target  cells.  It  will  therefore  be  of  great  possible  value  in  a  broad  range  of 
applications in cytotoxic gene therapy and significantly broadens the spectrum of available 
tools for AAV-based gene therapy. 
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1. Introduction 
Vectors derived from adeno-associated virus (AAV) hold promise as safe and efficient tools for 
gene therapy. Their desirable safety profile has been confirmed in a number of clinical trials  [1]. 
Vector administration does not elicit a strong cellular immune reaction [2], and the risk of unintended 
integration into the human genome is low [3,4]. Research efforts aimed at clinical application of AAV 
vectors are focused on increasing target specificity and transduction efficiency on the one hand and on 
evaluating suitable therapeutic transgenes on the other. The spectrum of strategies in the former field is 
wide [5,6]. It includes the exploitation of the natural diversity of AAV serotypes [7], the insertion of 
targeted peptides [8–10], the use of bispecific conjugates [11–13], and the insertion of random peptide 
libraries exposed at the capsid surface, which enables the identification of suitable capsid variants by 
biopanning [14–18]. 
The development of AAV vectors for cancer therapy has hitherto been focused on anti-angiogenic, 
immunomodulatory, and suicide genes, or on genes that mediate cell repair [19]. Cell death has been 
achieved using the herpes simplex virus thymidine kinase (HSV-tk) gene [20–22]; which exerts its 
toxic effect only after ganciclovir administration, as well as the pro-apoptotic TRAIL gene [23,24]. 
We set out to expand the arsenal of toxic AAV vectors. The production of vectors carrying strong 
toxic genes can be hampered by uncontrolled expression of these genes in the cell lines used for 
packaging. While specific promoters may be an option to circumvent this problem, they may not be 
available for a given target cell type of interest or may not be strong enough to achieve adequate 
transgene  expression  levels  in  the  target  cell  [25].  We  thus  aimed  to  establish  a  system  for  the 
production of cytotoxic AAV vectors under the control of a strong unspecific promoter. Our approach 
is based on transcriptional repression of toxic genes by a Tet repressor/operator system [26]. We used 
this system to produce novel cytotoxic vectors containing the genes coding for the catalytically active 
fragment of diphtheria toxin (DTA) [27] and the pro-apoptotic PUMA protein [28].  
2. Materials and Methods 
2.1. Cell Lines 
Cells were cultured in a humidified atmosphere at 37 ° C and 5% CO2. HEK293T cells (kindly 
provided by David Baltimore, California Institute of Technology, Pasadena, CA), HeLa cells (obtained 
from American Type Culture Collection (ATCC), Manassas, VA), and SiHa cells (kindly provided by 
Jens Hasskarl, University of Freiburg Medical Center, Freiburg) were cultured in Dulbecco’s Modified 
Eagle  Medium  (Invitrogen,  Carlsbad,  CA)  containing  10%  fetal  bovine  serum  (Biochrom,  Berlin, 
Germany)  and  1%  of  a  penicillin/streptomycin  solution  (011  units/mL  penicillin  G/100  μg/mL 
streptomycin, Invitrogen). HEK293T T-REx cells (Invitrogen) were cultured in Dulbecco’s Modified 
Eagle Medium containing 10% tetracycline-free fetal bovine serum (PAA Laboratories, Pasching), 1% 
penicillin/streptomycin, and 5 μg/mL blasticidin (Invitrogen). RPMI 8226 cells (obtained from ATCC) 
were cultured in  Iscove’s Modified Dulbecco’s Medium  (Invitrogen)  containing 10% fetal bovine 
serum and 1% penicillin/streptomycin. Toxins 2010, 2  
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2.2. Primary Murine Breast Cancer Cells 
These  cells  were  obtained  from  2-3-month-old  female  PymT  mice  (Jackson  Laboratories,  Bar 
Harbor, MN) [29]. All procedures involving the use and care of animals were performed according to 
the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of 
Health (NIH Publication No. 85-23, revised 1996) and the German animal protection code. Primary 
tumor  cells  were  obtained  by  mechanical  and  enzymatic  dissociation  of  solid  PymT-induced 
carcinomas as previously described [17]. 
2.3. pAAVTetO2 Plasmid Backbone 
To create pAAVTetO2 (Figure 1), pAAV-MCS (Stratagene, La Jolla, CA) was digested with NotI, 
and the 2891 bp backbone fragment providing the AAV inverted terminal repeat sequences as well as 
the ampicillin resistance gene was blunted with the E. coli DNA polymerase I Klenow fragment and 
Antarctic phosphatase. This fragment was ligated with the 1133 bp fragment obtained by digesting 
pcDNA4/TO (Invitrogen) with PvuII and NruI, which provides the CMV promoter, two tetO2 operator 
sequences, a multiple cloning site (MCS), and a BGH polyadenylation signal. 
Figure 1. Key features of the pAAVTetO2 plasmid backbone and derivative constructs. 
The  construct  provides  inverted  terminal  repeat  sequences  (ITR),  the  cytomegalovirus 
immediate early promoter (CMV), two tet operator sequences  (TetO2), and the bovine 
growth hormone polyadenylation signal (BGH pA). In the presence of the Tet repressor 
(TR), the transcription of toxic  genes is  inhibited (top), but it  is  enabled in its  absence 
(center). The toxic genes and reporter genes cloned into pAAVTetO2 are listed at the bottom. 
 
2.4. pAAVTetO2-Based Transgene Constructs 
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pTRUFluc  [30]  into  the  pAAVTetO2  MCS.  To  obtain  pAAVTetO2-DTA,  the  gene  encoding  the 
catalytic  domain  of  diphtheria  toxin  A  was  amplified  from  pDT201  (ATCC)  by  PCR,  using  the 
forward  primer  5'-TCGAAGCTTATGGGCGCTGATGATGTT-3'  introducing  an  ATG  start  codon  
and  the  reverse  primer  5'-TCGCTCGAGTCATCGCCTGACACGATT-3'  introducing  a  TGA  stop 
codon [31]. The PCR product was digested with HindIII/XhoI and inserted into the pAAVTetO2 MCS. 
To  create  pAAVTetO2-PUMA,  the  sequence  coding  for  the  murine  PUMA  protein,  with  an  
amino-terminal  FLAG  tag,  was  amplified  from  pEF-PUMA  (kindly  provided  by  
Christoph  Borner,  University  of  Freiburg  Medical  Center)  by  PCR  using  the  
forward  primer  5'-ATGGACTACAAGGACGATGACGACA-3'  and  the  reverse  primer  
5'-TCGAAGCTTATGGACTACAAGGACGATGACGACA-3'. The PCR product was digested with 
HindIII/XhoI and inserted into the pAAVTetO2 MCS. The integrity of toxic gene inserts and flanking 
regions were verified by sequencing (GATC Biotech, Konstanz). 
2.5. Production of Recombinant rAAV Vectors 
Recombinant AAV vectors were produced in the absence of adenovirus, with rep and cap genes 
provided  on  the  pXX2  plasmid  and  minimal  adenoviral  helper  sequences  provided  on  the  pXX6 
plasmid [32]. Packaging cells (HEK293T T-REx for toxic constructs, or HEK293T cells for non-toxic 
reporter constructs) were grown to about 50% confluency and transfected with pXX2, pXX6, and a 
plasmid carrying the transgene of interest using the PolyFect transfection reagent (Qiagen). For the 
production of targeted capsid variants, appropriate derivatives of the pXX2-187 plasmid [16] containing 
a cloning site for the insertion of peptide coding regions at amino acid position R588 were used.  
The transgenes of interest were contained in the pAAVTetO2 constructs created as described above. 
Alternatively,  the  pTRUF-CMV-eGFP  [15]  was  used  as  a  reporter  construct.  Vectors  were  
harvested 3–5 days after transfection by resuspending cells detached from the culture dish in PBS-MK 
(041 mM NaCl, 5.5 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, 1 mM MgCl2), followed by cell 
lysis  via  three  freeze-thaw  cycles.  Cellular  DNA  and  RNA  were  removed  by  incubation  with 
benzonase (Sigma) at >350 U/mL at 37 ° C for 30 minutes. Samples were centrifuged, and supernatants 
containing AAV vectors were stored at −80 ° C. If required, vector preparations were purified using the 
iodixanol  gradient  centrifugation  method  [33].  Solutions  containing  vectors  were  underlaid  with 
increasing concentrations of iodixanol (15%–54%) and centrifuged at 350,000 ×  g for 70 minutes, and 
the 40% iodixanol fraction containing the purified AAV vectors was stored at −80 ° C. 
2.6. Titration of AAV Libraries and Recombinant AAV Vectors 
The AAV vector capsid titers were determined as described by an ELISA (Progen, Heidelberg). The 
genomic titers of recombinant AAV vectors were determined by quantitative PCR using the Absolute 
SYBR Green fluorescein master mix (Abgene, Epsom) on a MyiQ cycler (Bio-Rad, Hercules, CA), 
using  the  primers  5'-GGCGGAGTTGTTACGACAT-3'  and  5'-GGGACTTTCCTACTTGGCA-3' 
specific  for  the  CMV  promoter  region.  The  genomic  titers  of  AAV  libraries  were  
determined  by  quantitative  PCR,  using  the  primers  5'-GCAGTATGGTGTATCTACCAA-3'  
and 5'-GCCTGGAAGAACGCCTTGTGT-3' specific for the insert region. Toxins 2010, 2  
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2.7. Luciferase Gene Transduction 
To  analyze  luciferase  gene  transduction,  10
4  primary  PymT  tumor  cells  per  well  were  seeded  
in 24-well plates and incubated with AAV-luciferase vectors at an multiplicity of infection (MOI)  
of 10
4 vector genomes/cell. 72 hours later, luciferase activities in cellular lysates were measured in a 
luminometer (Berthold  Centro LB 960) using the Promega luciferase assay (Promega, Mannheim) 
according to the manufacturer’s instructions. Values were normalized to protein levels in each probe 
determined by a Bradford assay (Bio-Rad). For analysis of pAAVTetO2-luciferase constructs, 293T  
T-REx cells were seeded at a density of 5 ×  10
3 cells per well and were transfected with 80 ng of DNA 
per well using Lipofectamine (Invitrogen). One day after transfection, the medium was replaced by 
fresh medium with or without 1 µg/mL tetracycline. Luciferase activity in one-tenth of the lysate 
volume obtained from each well was analyzed. 
2.8. Flow Cytometry 
To analyze gene transduction by AAV vectors harboring the enhanced green fluorescent protein 
(GFP),  5  ×  10
4  cells  per  well  of  PymT  cells  were  seeded  in  24-well  plates  and  incubated  with  
AAV-GFP vectors at an MOI of 10
3 or 10
4 vector genomes/cell. After three days, cells were harvested 
and  GFP  reporter  gene  expression  was  determined  using  a  flow  cytometer  (FACSCalibur,  BD 
Biosciences, Heidelberg) and CellQuest Pro analysis software. For detection of apoptotic and necrotic 
processes,  RPMI  8226  cells  were  stained  with  an  annexin  V-GFP  conjugate  and  with  propidium 
iodide. GFP-/PI- cells were gated as viable, GFP+/PI- cells were gated as apoptotic, and GFP+/PI+ 
cells were gated as necrotic. For analysis of the inhibition of GFP synthesis, 2 ×  10
4 cells were seeded. 
2.9. Viability/toxicity Assay 
Toxic effects on cells were analyzed using a colorimetric assay based on the reduction of MTT  
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to a formazan salt in viable cells [34,35]. 
Cells were incubated with medium containing 500 µg/mL MTT (Invitrogen) for four hours, and the 
absorbance of formazan crystals dissolved in SDS/HCl was measured at 570 nm in a spectrophotometer. 
2.10. Statistics 
The significance of results was analyzed using Student’s t-test (one-sided) at α = 5%. 
3. Results 
3.1. A Novel Tet-Regulated Plasmid for Production of Toxic AAV Vectors 
We created a novel plasmid construct for production of AAV vectors carrying toxic genes under the 
control of the cytomegalovirus immediate early promoter. This construct, designated pAAVTetO2, 
provides  the  inverted  terminal  repeat  sequences  required  for  packaging  of  transgenes  into  vector 
capsids, as well as tet operator sequences to allow for transcriptional inhibition of transgenes by the 
Tet repressor (Figure 1). The repressor can be inactivated by addition of tetracycline. To verify that 
transcription  from  pAAVTetO2  constructs  can  be  inhibited  by  the  Tet  repressor/tet  operator Toxins 2010, 2  
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mechanism,  we  transfected  HEK293T  T-REx  cells  stably  expressing  the  Tet  repressor  with  a 
pAAVTetO2  construct  containing  the  firefly  luciferase  reporter  gene  (pAAVTetO2-luc),  and 
luminescence was assayed. In the absence of tetracycline, luciferase activity amounted to less than 2% 
of the value observed in the presence of tetracycline (see Appendix Figure 1), demonstrating that the 
Tet repressor inhibits transcription efficiently. 
3.2. Production of Toxic Vectors 
Genes coding for DTA and PUMA were cloned into pAAVTetO2. The resulting plasmid constructs 
were used for the production of toxic vectors with wildtype AAV-2 capsid. Vectors were produced  
in  293T  T-REx  cells  stably  expressing  the  Tet  repressor.  Vectors  carrying  the  PUMA  gene 
(AAVTetO2-PUMA) could be produced in the same concentrations as non-toxic vectors produced 
using an identical setting (with titers in the range of 10
11–10
12 vector genomes/mL) if the packaging 
cells (HEK293T) were transfected with plasmid constructs containing the transgene of interest in the 
range of 5 ×  10
4 plasmids per cell. The titers obtained for DTA vectors were typically two to three 
orders of magnitude lower, most probably because of residual expression of the DTA protein, which 
inhibits protein synthesis even in minute quantities. However, titers could be slightly improved by 
lowering the copy number of the toxic pAAVTetO2-DTA construct in the packaging cell line, with 
maximum titers achieved for 100–1,000 copies of pAAVTetO2 per cell. We could further show that 
the presence of the Tet repressor (pcDNA6/TR) actually results in increased titers for DTA vectors, 
confirming the validity of our approach (Figure 2). 
Figure 2. Contributions of the Tet repressor/operator system to increasing titers of toxic 
vectors.  Comparison  of  titers  of  vectors  carrying  the  diphtheria  toxin  A  gene  
(AAVTetO2-DTA) produced under different conditions: without transcriptional repression 
(black), in the presence of the Tet repressor, and in the presence of the Tet repressor and  
of 1 µg/mL tetracycline. For each of these conditions, different copy numbers of the DTA 
gene  per  packaging  cell  were  evaluated.  The  data  are  mean  values  ±   SD  from  two 
independent experiments. 
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3.3. Evaluation of Novel Toxic Vectors 
We  evaluated  the  toxic  AAVTetO2-DTA  and  AAVTetO2-PUMA  vectors  on  HeLa  and  SiHa 
cervical carcinoma cell lines, and on the RPMI 8226 myeloma cell line. AAVTetO2-DTA vectors 
were purified via iodixanol density gradient ultracentrifugation and were evaluated at a maximum 
multiplicity of infection (MOI) of 5 ×  10
3 vector genomes per cell. The AAVTetO2-PUMA vector was 
evaluated at a maximum MOI of 10
5 vector genomes per cell without further purification. For the 
analysis of toxic effects, cells were seeded in a 96-well plate at a density of 5 ×  10
3 cells per well one 
day  before  transduction.  Toxic  effects  were  analyzed  by  an  MTT  viability  assay  five  days  after 
transduction. For the AAVTetO2-DTA vector, a significant toxic effect could be detected on HeLa 
cells,  SiHa  cells,  and  RPMI  8226  cells  at  an  MOI  of  5  ×  10
3  vector  genomes  per  cell.  The  
AAVTetO2-PUMA vector had a significant effect on HeLa cells and RPMI 8226 cells at an MOI  
of 10
5, but not on SiHa cells (Figure 3A). 
Considering  that  the  PUMA  protein  can  sensitize  cells  to  additional  toxic  stimuli  [36,37],  we 
evaluated  the  effects  of  the  AAVTetO2-PUMA  vector  in  combination  with  doxorubicin 
administration. For that purpose, RPMI 8226 cells were transduced with AAVTetO2-PUMA at an 
MOI of 10
4 vector genomes per cell. Doxorubicin was added to the samples one day after transduction. 
Five days after transduction, toxic effects were analyzed by an MTT assay. Cells transduced with the 
AAVTetO2-PUMA vector were more sensitive to doxorubicin at a concentration of 5–10 nM than 
controls transduced with a non-toxic vector (Figure 3B). 
Figure 3. Functionality of novel toxic AAV vectors carrying toxic genes. (A) Toxic effects 
on  a  panel  of  tumor  cell  lines.  The  data  are  mean  values  ±   SD  from  three  independent 
experiments  each  done  in  triplicates;  (B) Combined application of the AAVTetO2-PUMA 
vector and doxorubicin. The data are mean values ±  SD from two independent experiments, each 
done in triplicate.  Asterisks  indicate  a  significant toxic  effect compared to  administration  of  a  
non-toxic vector (AAVTetO2). 
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Figure 3. Cont.  
 
Figure 4. Cell death in cells transduced with DTA and PUMA vectors. Identification of 
apoptotic, necrotic, and viable cells by flow cytometry. Top: Two-dimensional staining 
intensity plots. Bottom: Percentage of cells gated as viable, apoptotic, and necrotic (mean 
values from an experiment done in triplicates). 
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RPMI  8226  cells  transduced  with  the  AAVTetO2-DTA  (MOI  of  5  ×   10
3  vg/cell)  and  
AAVTetO2-PUMA (MOI of 10
5 vg/cell) vectors were analyzed by flow cytometry to detect apoptotic 
and necrotic processes. Five days after transduction, a substantial fraction of cells transduced with 
toxic vectors, but  not  with controls,  was  gated  as  apoptotic, suggesting that these vectors  act  via 
pathways that involve apoptosis (Figure 4). 
3.4. Targeted Delivery of the DTA Vector to PymT Cells 
Once  the  functionality  of  the  DTA  gene  when  delivered  via  a  wildtype  AAV-2  capsid  was 
confirmed, we set out to produce a targeted variant of the DTA vector. For this purpose, we selected a 
capsid  modification  previously  developed  by  our  group  [17]  which  mediates  enhanced  in  vitro 
transduction  of  mammary  tumor  cells  from  mice  carrying  the  polyomavirus  middle  T  antigen  
(PymT cells). In this capsid variant, which was identified by biopanning of AAV capsids containing 
random peptide libraries [17], the amino acid sequence RGDLGLS is inserted at position R588 of the 
viral capsid protein VP1. The cell-type specificity of RGDLGLS capsids was tested on a panel of  
non-malignant cell lines and primary murine cells. While 3T3 mouse fibroblasts and primary mouse 
hepatocytes were not permissive for transduction with RGDLGLS AAV luciferase vectors, they could 
be efficiently transduced by vectors with wildtype AAV capsids. Further, immunostaining showed that 
selected AAV vectors selectively transduce cytokeratin positive primary PymT breast cancer cells in 
primary co-cultured tumor tissue, suggesting target specificity of AAV with RGDLGLS capsid inserts 
(data not shown). 
Figure  5.  Effects  of the diphtheria toxin  A gene on murine PymT breast  tumor cells, 
delivered via an AAV vector with targeted capsid structure (RGDLGLS). (A) The targeted 
vector (RGDLGLS-DTA) has a strong toxic effect on PymT cancer cells compared to a 
vector with a random sequence capsid insertion or the DTA vectors with wildtype AAV 
capsid. The data are mean values ±  SD from triplicates. (B) Inhibition of eGFP synthesis in 
PymT  cells  transduced  with  the  RGDLGLS-DTA  vector  as  assayed  by  fluorescence 
microscopy. Cells are visualized by cytokeratine staining. The percentage of cells gated as 
GFP-positive by flow cytometry in a parallel experiment is indicated. The data are mean 
values ±  SD from triplicates. 
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Figure 5. Cont.  
 
 
We produced vectors with the capsid peptide insertion RGDLGLS and harboring the DTA gene. 
Vectors with capsids containing the random amino acid sequence VRRPRFW (at position R588) as 
well as vectors with wildtype capsids were produced as non-targeted controls. PymT primary breast 
cancer cells were transduced with these vectors at an MOI of 5 ×  10
3. A strong toxic effect of the 
targeted DTA vectors was detected after four days in an MTT viability assay compared to the effect 
caused by the control vectors (Figure 5A). 
To  complement  these  experiments,  we  analyzed  the  inhibitory  effect  of  the  targeted  vector  on 
protein synthesis. PymT cells were transduced with the RGDLGLS-DTA vector or the control DTA 
vector, followed by transduction with an RGDLGLS vector harboring the egfp gene. Following DTA 
transduction, GFP expression was reduced in samples transduced with the RGDLGLS-DTA vector, 
but not with the control DTA vector, as analyzed by fluorescence microscopy and flow cytometry 
(Figure 5B). 
4. Discussion 
Production  of  cytotoxic  vectors  for  therapeutic  gene  delivery  is  challenging  as  uncontrolled 
cytotoxic gene expression can suppress protein synthesis and/or viability in producer cells. Here, we 
set out to expand the potential of AAV vectors for experimental tumor therapy. We established and 
used a transcriptional repression system to produce novel AAV vectors carrying the genes coding for 
diphtheria  toxin  A  (DTA)  and  the  pro-apoptotic  PUMA  protein.  In  several  proof  of  principle 
experiments, we showed that the vectors produced with our method and carrying the genes coding for 
the DTA protein and the PUMA protein under the control of the CMV promoter are functional, and 
both in a targeted and non-targeted vector capsid context. 
The characteristics of the vectors presented here differ from those reported for experimental vectors 
already  available.  Among  the  approaches  described  previously,  toxic  vectors  based  on  the  herpes 
simplex  virus  thymidine  kinase  gene  play  a  prominent  role.  These  vectors  exert  their  effect  only 
indirectly by causing the conversion of a prodrug to a toxic product. In contrast, we aimed to generate 
toxic  vectors  that  are  directly  toxic  to  the  cells  they  transduce,  without  the  need  for  prodrug 
administration. Furthermore, we intended to develop vectors with the strongest possible toxic potential 
B Toxins 2010, 2  
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that should be applicable to a broad range of cancer cells. Therefore we chose a system delivering 
toxic genes under the control of a strong and non-tissue-specific promoter such as the CMV promoter, 
while tissue specificity is supposed to be conferred by a target cell-specific capsid. 
To face the challenge of cytotoxicity in vector-producing cells, we propose a novel strategy for 
production  of  toxic  AAV  vectors  based  on  transcriptional  repression  of  toxic  genes.  While  we 
demonstrate that the system is functional, we recognize that its contribution is limited in the context of 
genes coding for proteins as potent as diphtheria toxin A, which can be considerably toxic even in 
minute quantities [40]. Nevertheless, the option to produce vectors carrying toxic genes under the 
control of a strong and unspecific promoter may be interesting for the evaluation of various toxic 
candidate vectors on a variety of target cell types. While of broad utility, the system presented here 
may  be  further  optimized  in  several  ways,  depending  upon  the  context  in  which  the  vectors  are 
intended for application. In certain target cell types, the system may be further optimized by the use of 
a specific promoter, if available. In addition, the activity of toxic proteins in the cells used for vector 
production might be inhibited by transgene-specific means, e.g., via anti-sense/siRNA or via inhibition 
of  the  protein  A  complex.  Another  approach  to  further  enhance  vector  productivity  may  be  the 
generation of toxic vectors in which toxic genes become active only through the excision of spacer 
DNA by Cre-recombinase delivered via a second vector. This strategy, which has been successfully 
evaluated using adenovirus [31], may also hold promise in the AAV context. 
Broadening the spectrum of toxic vectors is desirable as it provides the option to choose the most 
efficient mechanism of cell killing depending on the target cells. For instance, the above-mentioned 
HSV-tk-based vectors have been reported to cause toxic effects on untransduced cells in the vicinity of 
cells expressing HSV-tk [38]. This “bystander effect” can be exploited to kill a tumor even if only a 
fraction of cells can be transduced and even extends to cells of different origin than the initial target 
cell [22]. In contrast, toxic effects of the DTA gene are restricted to cells that actually express it [39]. 
This may encourage the further development of DTA-based vectors such as the ones presented here for 
specific killing of widely disseminated malignant cells, as found in metastatic disease, provided, of 
course, that target specificity is sufficiently high. 
Our  data  suggest  that  the  toxic  vectors  described  here  may  be  further  developed  for  targeted 
therapy. While transgene expression in cells other than the actual target may be tolerated in other 
fields,  specificity  is  paramount  in  cancer  therapy.  AAV  capsid  modifications  can  improve  the 
transduction  efficiency  for  a  target  cell  type  of  interest,  but  in  some  instances  this  may  lead  to 
increased transduction of other tissues as well [17]. Therefore, our novel cytotoxic AAV vectors are 
currently  being  further  developed  for  systemic  gene  transfer  in  vivo  as  future  advancement  in  
AAV-based  experimental  cancer  therapy  will  rely  on  the  combination  of  suitable  transgenes  with 
efficient and specific promoters, as well as on the use of receptor-targeted vector capsids. 
5. Conclusions 
Vectors based on adeno-associated virus (AAV) are promising for cancer-directed cytotoxic gene 
transfer. We produced novel AAV vectors carrying the genes coding for diphtheria toxin A and the 
pro-apoptotic PUMA protein and demonstrated that these novel vectors can be used to efficiently kill a 
broad range of tumor cells, both in receptor-targeted and native capsid contexts. Taken together, the Toxins 2010, 2  
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vector production and application system presented here broaden the spectrum of tools available for 
cytotoxic cancer gene therapy based on AAV vectors. The cloning and production system provides 
excellent versatility in exchanging promotors, transgenes and capsid specificity for certain target cells 
and will therefore be of great possible value in a broad range of applications in cytotoxic gene therapy. 
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Appendix 
Figure  1.  Functionality  of  transcriptional  regulation  by  the  Tet  repressor/Tet  operator 
system  in  the context  of the novel construct  pAAVTetO2.  Analysis  of luciferase  activity  
in 293T T-REx cells stably expressing the Tet repressor after transfection with the firefly luciferase 
gene under the control of the tet operator (pAAVTetO2-luc). Luciferase activity in cells transfected 
with a construct without tet operator control (pTRUFluc) is shown for comparison. The data are 
mean values ±  SD from two independent experiments, each done in triplicates.  
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